IM Cannabis Corp., a leading medical cannabis company with operations in Israel and Germany, has secured a total of approximately US$2.17 million in debt financing through note purchase agreements with an arm's length third-party lender. The financing comprises two notes: the first, issued on January 7, 2026, is for US$1,538,749, and the second, dated January 20, 2026, is for US$632,911.50, both with a 10% original issuance discount. About US$500,000 of the proceeds have been allocated to repay existing creditors, with the remainder supporting general corporate purposes and operational initiatives. The second note carries an 8% annual interest rate, rising to 14% upon default, and matures 18 months from issuance. IM Cannabis has agreed to register the resale of shares issuable upon conversion of these notes with the U.S. SEC. All securities issued are subject to standard holding periods and regulatory legends.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IM Cannabis Corp. published the original content used to generate this news brief via PR Newswire (Ref. ID: LN71322) on January 26, 2026, and is solely responsible for the information contained therein.